Study of AHB-171 in Chronic Hepatitis B Participants
An Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of AHB-171 Injection in Participants With Chronic Hepatitis B
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Fujian
-
Xiamen, Fujian, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Guangxi
-
Nanning, Guangxi, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Henan
-
Zhengzhou, Henan, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Jiangsu
-
Changzhou, Jiangsu, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Jilin
-
Jilin City, Jilin, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
-
Sichuang
-
Chengdu, Sichuang, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- AusperBio Investigational Site
-
Contact:
- Bella Lu
- Phone Number: 0571-86959519
- Email: clinicaltrial@ausperbio.com
-
Contact:
- Email: clinicaltrial@ausperbio.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to fully understand and sign the informed consent form (ICF).
- Male or female participants, aged 18-65 years (inclusive).
- Body mass index (BMI) meeting the predefined eligibility range.
- Chronic hepatitis B (CHB) participants with HBsAg or HBV DNA positivity for ≥6 months at screening.
- At screening, participants meeting predefined ranges of HBsAg, HBV DNA, and ALT according to prior nucleos(t)ide analogue (NA) treatment history (stable prior treatment or treatment-naive), and meeting corresponding prior antiviral treatment duration requirements.
- Adopt effective contraceptive measures as required
Exclusion Criteria:
- History of any severe systemic disease or malignancy other than chronic HBV infection which, in the opinion of the investigator, makes the subject unsuitable for study participation.
- Prior history of solid organ or hematopoietic stem cell transplantation.
- History of any other liver disease that the investigator considers unsuitable for trial.History of autoimmune disease or diseases with potential immune activation risk.
- History or presence of hepatic decompensation at screening.
- History of primary liver cancer, or diagnosis/suspected liver cancer at screening.
- Imaging or histological evidence of significant liver fibrosis or cirrhosis within 12 months prior to screening, or a liver stiffness measurement indicative of significant fibrosis or cirrhosis at screening. Major trauma or major surgery within 12 weeks prior to screening
- History of severe allergies (e.g., to ≥2 allergens) or severe allergy to any component of the study drug, or in the opinion of the investigator, makes the subject unsuitable for participation.
- Severe infection requiring intravenous anti-infective therapy within 2 weeks prior to screening (excluding chronic HBV infection).
- History of drug abuse, or alcoholism.
- Blood donation or blood loss exceeding the specified volume within 12 weeks prior to screening, or planned blood donation during the trial period.
- Use of immunosuppressants, immunomodulators, cytotoxic drugs, or biologics within 6 months prior to screening.
- Use of any oligonucleotide drugs or interferon therapy within 12 months prior to screening.
- Vaccination within 4 weeks prior to screening, or planned vaccination during the trial period.
- Presence of tattoos, active skin diseases, or other conditions that may interfere with subcutaneous drug administration or observation of injection site reactions.
- Clinically significant abnormal electrocardiogram (ECG) at screening.
- Tested positive for HIV,HCV or active syphilis infection.
- Uncontrolled hypertension at screening.
- Clinically significant abnormal laboratory test as specified in protocol at screening.
- Currently participating in another clinical trials, or within the washout period.
- Any other condition or factor which, in the opinion of the investigator, makes the subject unsuitable for trial participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AHB-171 in Treatment CHB
|
Subcutaneous injection
|
|
Experimental: AHB-171 in Naïve CHB
|
Subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants with HBsAg <10 IU/mL and HBV DNA < LLOQ (10 IU/mL)
Time Frame: Up to 90 days
|
Up to 90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants achieving complete response (HBsAg <0.05 IU/mL and HBV DNA < LLOQ)
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with HBsAg decline from baseline of <0.5, ≥0.5, ≥1.0, ≥1.5, ≥2.0, ≥3.0 log₁₀ IU/mL at each visi
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with HBsAg <100 IU/mL, <10 IU/mL, <1 IU/mL at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants achieving HBsAg clearance (HBsAg <0.05 IU/mL) at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with HBV DNA < LLOQ (10 IU/mL) at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants achieving complete response (HBsAg <0.05 IU/mL and HBV DNA < LLOQ) at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with anti-HBs seroconversion (HBsAg clearance and HBsAb >10 IU/L) at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Absolute or log change from baseline for HBsAg at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Absolute or log change from baseline for HBV RNA at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Absolute or log change from baseline for HBcrAg at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Absolute or log change from baseline for HBeAg at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Absolute or log change from baseline for HBeAb at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with baseline ALT > ULN achieving ALT normalization, and time to ALT normalization
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Incidence and severity of treatment-emergent adverse events (TEAE) and serious adverse events (SAE)
Time Frame: Up to 90 days
|
CTCAE will be used to describe severity.
|
Up to 90 days
|
|
Proportion of participants with clinically significant abnormalities in laboratory tests
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with clinically significant abnormalities in ECG
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with clinically significant abnormalities in physical examinations and vital signs
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Changes in ECG from baseline
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with HBsAg decline ≥2.0 log₁₀ IU/mL
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Plasma concentration of AHB-171 at different time points
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Proportion of participants with detectable anti-drug antibody (ADA)
Time Frame: Up to 90 days
|
Up to 90 days
|
|
|
Change of HBsAg (log₁₀ IU/mL) from baseline and maximum reduction at each visit
Time Frame: Up to 90 days
|
Up to 90 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Organizing Pneumonia
- Immune System Diseases
- Infections
- Virus Diseases
- Respiratory Tract Diseases
- Digestive System Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Liver Diseases
- Hepatitis, Viral, Human
- Communicable Diseases
- DNA Virus Infections
- Hepadnaviridae Infections
- Bronchiolitis Obliterans
- Bronchiolitis
- Bronchitis
- Hepatitis
- Graft vs Host Disease
- Bronchiolitis Obliterans Syndrome
- Hepatitis B
Other Study ID Numbers
Other Study ID Numbers
- AB-17-8003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.